We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/5/2020 09:59 | News coming soon.Gl :-) | moneymunch | |
05/5/2020 09:43 | Looks on to close that gap but not counting chickens! | toffeeman | |
05/5/2020 08:33 | Looking good and strong...Gla ;-) | moneymunch | |
04/5/2020 16:47 | telegram group if anyone wants in just started all help welcome | colin12345678 | |
04/5/2020 16:32 | Tomorrow would be nice | peanut100 | |
04/5/2020 15:51 | Looking good and strong...good news could drop at anytime. ;-) | moneymunch | |
04/5/2020 11:06 | Perfectly poised for positive news...confirmation of the new CEO and an Update on SFX-01, very possibly for Covid treatment trials. Gla :-) | moneymunch | |
04/5/2020 11:04 | And it doesn't look like it will here either! | toffeeman | |
04/5/2020 08:29 | Couldn't get a spread bet on so bought a few to sell on the gap close (if it happens) - - it didn't with C4XD!! | toffeeman | |
04/5/2020 08:05 | Looking good and strong!!! Gla holders On and UP!!! ;-) | moneymunch | |
01/5/2020 17:34 | Back in again mid morning,more luck than judgement to catch the rise:) NFX also up today. | bmnsa | |
01/5/2020 16:26 | Don't blink then ! | arab3 | |
01/5/2020 16:24 | See my post 1617, re French Bio.., maybe something similar in the pipeline for EVG. Gl :-) Currently, there are no clinical studies on sulforaphane versus covid-19, "so we are forced to use therapeutic approaches based on previous research. Sulforaphane has been shown to be safe for consumption and that it is commercially available. I think it can be an important treatment available to the citizen in the current viral pandemic "continues the boss of the laboratory Nutrinov. Nutrinov and its researchers therefore hope to be able to launch a clinical study to assess the efficacy of sulforaphane against the current virus. | moneymunch | |
01/5/2020 16:23 | Hi Nobby :) | toffeeman | |
01/5/2020 16:19 | Wow. You blink and you miss it... | nobbygnome | |
01/5/2020 16:17 | Close the gap back to 16p for starters, news of new CEO coming, and if Sfx-01 is selected for clinical trials for Covid-19, then the sky's the limit. Gla :-) | moneymunch | |
01/5/2020 16:05 | Wow another rocket going skyward, got CTEA this week (medical digital passports) and they have been flying nicely although they are so small I fancy they can go many times higher. What are the price expectations on Evgen? | czar | |
01/5/2020 15:37 | Market short of stock, any news here Monday and massive squeeze. | peanut100 | |
01/5/2020 15:28 | 10p plus close on the cards, fingers crossed for news this coming week. Gla :-) | moneymunch | |
01/5/2020 15:27 | Just paid above the ask. | awise355 | |
01/5/2020 13:29 | Good luck with the new drug blakeysangel and glad to hear you are getting through lock down without the need of a divorce lawyer, unlike a lot of people during this time I suspect! | lovewinshatelosses | |
01/5/2020 12:31 | Looking good and strong, confirmation of the new CEO is likely to add significant value, and news on their drug development collaborations with several Universities, who are all now heavily involved in Covid-19 treatment research, could drop at anytime, and if SFX-01 is confirmed as a likely candidate for Covid-19 trials, then this will fly. Gla :-) | moneymunch | |
01/5/2020 06:48 | Translated from French to English...Gla ;-) Coronanvirus: Nutrinov laboratory to launch research to evaluate the efficacy of sulforaphane Thursday April 30 Around the world, the race is on to find treatments for the coronavirus. Near Rennes, a laboratory specializing in health and nutrition wants to launch a clinical trial on sulforaphane, a natural compound with antiviral properties. Doctors often say, by being careful what you eat, people can ease their symptoms and heal faster. Several epidemiological studies have notably identified the important role of fruits and vegetables. A healthy diet and physical activity, for example, reduce the risk of cancer. Some substances are known for their antiviral properties. One of them is of particular interest to researchers and scientists in the Nutrinov laboratory located near Reindeer. He specializes in health and nutrition. Its researchers are particularly interested in sulforaphane, present in cruciferous vegetables such as broccoli and kale. It has several properties that participate in cell protection. It has also been shown to have antiviral properties. A prophylactic and curative effect against covid-19? "This molecule there, we know that it has antiviral, antibacterial and anticancer properties. We have done clinical studies with people who had prostate cancer. We have shown that it can help slow the evolution of pathology "explain Dr. Bernard Cipolla, surgeon oncologist in urology and Théo Efstathiou who heads the Nutrinov Analyzes & Research laboratory. "In terms of antiviral activity, we conducted another clinical study in 2014 on mice targeted to pulmonary edema. We injected the H1-N1 virus in mice. A fortnight before, we had given sulforaphane and we noticed a clear reduction in the symptoms of pulmonary edema "indicates Théo Efstathiou. Currently, there are no clinical studies on sulforaphane versus covid-19, "so we are forced to use therapeutic approaches based on previous research. Sulforaphane has been shown to be safe for consumption and that it is commercially available. I think it can be an important treatment available to the citizen in the current viral pandemic "continues the boss of the laboratory Nutrinov. Nutrinov and its researchers therefore hope to be able to launch a clinical study to assess the efficacy of sulforaphane against the current virus. | moneymunch | |
30/4/2020 17:06 | (NADS in COVID-19 - short communication - version 1.1 - 1.5 A4 pages without references - 31.03.2020) Potent NRF2-activating dietary supplements (like resveratrol, curcumin, sulforaphane, “Asea redox supplement” [ARS] etc.) should be clinically tested as high-dose adjuvants in all types of medium and severe cases of aggressive respiratory viral infections (including Influenza A/B/C, measles, Coronavirus-related SARS, MERS, COVID-19) based on their extrapolated cytoprotective antioxidant effects Abstract This very short medical communication proposes that potent NRF2-activating dietary supplements (like resveratrol, sulforaphane, curcumin, “Asea redox supplement” [ARS] etc.) should be clinically tested as safe high-dose adjuvants (in various combinations) in all types of medium and severe cases of aggressive respiratory viral infections (including Influenza A/B/C, avian influenza, measles, Coronavirus-related SARS, MERS, COVID-19, etc., including those patients who have important comorbidities like HIV/AIDS, tuberculosis [TB] etc.) based on their extrapolated cytoprotective antioxidant effects (especially on the main vital organs: brain, heart, lungs, kidneys and liver), including the extrapolated strong cytoprotection offered by ARS on the cardiac muscle of DMD patients (which can be extrapolated to the lungs), like the author of this paper has demonstrated in past papers. Keywords: NRF2-activating dietary supplements, resveratrol, sulforaphane, curcumin, “Asea redox supplement” [ARS], respiratory viral infections, influenza A/B/C, avian influenza, measles, coronavirus, SARS, MERS, COVID-19, HIV/AIDS, tuberculosis [TB] | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions